Form 4 · Filed Jun 4, 2026, 01:04 AM UTC
XENE/Xenon Pharmaceuticals Inc.
GANNON STEVEN — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
5 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | A | other | 10,507 | — | — | 10,507 |
| Jun 3, 2026 | A | other | 1,593 | — | — | 1,593 |
| Jun 1, 2026 | M | other | 2,645 | — | — | 13,286 |
| Jun 1, 2026 | F | other | 1,416 | $53 | $75,629 | 11,870 |
| Jun 1, 2026 | M | other | 2,645 | — | — | 0 |
Source: SEC EDGAR raw filing ↗ · Accession 0001193125-26-256121